Mirus Capital AdvisorsMirus Capital Advisors

Mirus advised CTGT in its sale to Health Network Laboratories (HNL)

Allentown, PA — Jan. 14, 2019

Health Network Laboratories (HNL), a leader in high quality, innovative laboratory medicine services, announced today they have acquired Connective Tissue Gene Tests, LLC (CTGT), an internationally recognized provider of molecular diagnostic testing services for inherited genetic disorders that delivers clinically actionable diagnostic information to its worldwide customer base.

Founded in 2004 by two of the leading researchers in the field, James Hyland, M.D., Ph.D. and Leena Ala-Kokko, M.D., Ph.D., and based in Allentown, Pennsylvania, CTGT has been at the forefront of the constitutional genetic testing field for more than a decade. The Company uses its proprietary analytic methods, mutation database and technology to provide more than 3,300 unique tests covering over 1,000 genes. Its efficient systems and team of experts enable CTGT to provide concise and definitive results containing meaningful and focused data analysis, rapidly develop and deploy new tests, and offer consistently superior customer service and best-in-industry, turn-around times.

“CTGT is an important and exciting addition to HNL’s diagnostic service portfolio, allowing us to continue building on our heritage of innovation that provides best in class diagnostic services for the physicians and patients we serve,” said Dr. Peter Fisher, President and CEO of HNL.

According to Dr. Jeff Wisotzkey, HNL’s Clinical Lab Director and Scientific Officer, “The acquisition of CTGT will complement HNL’s comprehensive clinical genetic laboratory service programs in cancer, infectious disease, perinatal disease and pharmacogenomics by providing intellectual, bioinformatics and technical synergies amongst all the molecular genetic testing laboratories of HNL, and significantly enhance our capabilities in inherited disease diagnostic services.”

“We are excited about the future of CTGT,” said founders Drs. Hyland and Ala-Kokko. “HNL will benefit from CTGT’s innovative technologies and expertise in genetics. We are excited about HNL’s synergistic commitment to quality and customer service which has been so important to our clients.”

Operating for over 20 years, HNL is a leader in laboratory medicine that works with more than 10 hospital systems and has over 60 regional patient service centers. Each year, HNL generates more than 60 million clinical and anatomic pathology results for approximately 3 million patients and 12,000 healthcare providers.

Back to Transactions